Hotline: +86-18022463983    020-85206863

Global CAR-T Cell Immunotherapies for Cancer Market Research Report 2024

Published Date: 2024-03-29   |   Pages: 70   |   Tables: 137   |  Medical Care

The global CAR-T Cell Immunotherapies for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for CAR-T Cell Immunotherapies for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Cell Immunotherapies for Cancer.

Report Scope

The CAR-T Cell Immunotherapies for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CAR-T Cell Immunotherapies for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the CAR-T Cell Immunotherapies for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

NOVARTIS

Penn

Fosun Pharma

Celgene Corporation

Legend Biotech

SHEBA

JW Therapeutics

Protheragen

EXUMA Biotechnology

Segment by Type

CD19

BCMA

EPCAM

Segment by Application

Hematological Cancer

Solid Tumor

Other Oncological Disorders

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of CAR-T Cell Immunotherapies for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:


Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

 

Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

 

Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

 

Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

 

Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

 

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 CD19

1.2.3 BCMA

1.2.4 EPCAM

1.3 Market by Application

1.3.1 Global CAR-T Cell Immunotherapies for Cancer Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hematological Cancer

1.3.3 Solid Tumor

1.3.4 Other Oncological Disorders

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global CAR-T Cell Immunotherapies for Cancer Market Perspective (2019-2030)

2.2 CAR-T Cell Immunotherapies for Cancer Growth Trends by Region

2.2.1 Global CAR-T Cell Immunotherapies for Cancer Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 CAR-T Cell Immunotherapies for Cancer Historic Market Size by Region (2019-2024)

2.2.3 CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Region (2025-2030)

2.3 CAR-T Cell Immunotherapies for Cancer Market Dynamics

2.3.1 CAR-T Cell Immunotherapies for Cancer Industry Trends

2.3.2 CAR-T Cell Immunotherapies for Cancer Market Drivers

2.3.3 CAR-T Cell Immunotherapies for Cancer Market Challenges

2.3.4 CAR-T Cell Immunotherapies for Cancer Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top CAR-T Cell Immunotherapies for Cancer Players by Revenue

3.1.1 Global Top CAR-T Cell Immunotherapies for Cancer Players by Revenue (2019-2024)

3.1.2 Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Players (2019-2024)

3.2 Global CAR-T Cell Immunotherapies for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by CAR-T Cell Immunotherapies for Cancer Revenue

3.4 Global CAR-T Cell Immunotherapies for Cancer Market Concentration Ratio

3.4.1 Global CAR-T Cell Immunotherapies for Cancer Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by CAR-T Cell Immunotherapies for Cancer Revenue in 2023

3.5 CAR-T Cell Immunotherapies for Cancer Key Players Head office and Area Served

3.6 Key Players CAR-T Cell Immunotherapies for Cancer Product Solution and Service

3.7 Date of Enter into CAR-T Cell Immunotherapies for Cancer Market

3.8 Mergers & Acquisitions, Expansion Plans

4 CAR-T Cell Immunotherapies for Cancer Breakdown Data by Type

4.1 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Type (2019-2024)

4.2 Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Type (2025-2030)

5 CAR-T Cell Immunotherapies for Cancer Breakdown Data by Application

5.1 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Application (2019-2024)

5.2 Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)

6.2 North America CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)

6.4 North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)

7.2 Europe CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)

7.4 Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)

8.2 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2019-2024)

8.4 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)

9.2 Latin America CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)

9.4 Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size (2019-2030)

10.2 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024)

10.4 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 NOVARTIS

11.1.1 NOVARTIS Company Detail

11.1.2 NOVARTIS Business Overview

11.1.3 NOVARTIS CAR-T Cell Immunotherapies for Cancer Introduction

11.1.4 NOVARTIS Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.1.5 NOVARTIS Recent Development

11.2 Penn

11.2.1 Penn Company Detail

11.2.2 Penn Business Overview

11.2.3 Penn CAR-T Cell Immunotherapies for Cancer Introduction

11.2.4 Penn Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.2.5 Penn Recent Development

11.3 Fosun Pharma

11.3.1 Fosun Pharma Company Detail

11.3.2 Fosun Pharma Business Overview

11.3.3 Fosun Pharma CAR-T Cell Immunotherapies for Cancer Introduction

11.3.4 Fosun Pharma Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.3.5 Fosun Pharma Recent Development

11.4 Celgene Corporation

11.4.1 Celgene Corporation Company Detail

11.4.2 Celgene Corporation Business Overview

11.4.3 Celgene Corporation CAR-T Cell Immunotherapies for Cancer Introduction

11.4.4 Celgene Corporation Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.4.5 Celgene Corporation Recent Development

11.5 Legend Biotech

11.5.1 Legend Biotech Company Detail

11.5.2 Legend Biotech Business Overview

11.5.3 Legend Biotech CAR-T Cell Immunotherapies for Cancer Introduction

11.5.4 Legend Biotech Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.5.5 Legend Biotech Recent Development

11.6 SHEBA

11.6.1 SHEBA Company Detail

11.6.2 SHEBA Business Overview

11.6.3 SHEBA CAR-T Cell Immunotherapies for Cancer Introduction

11.6.4 SHEBA Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.6.5 SHEBA Recent Development

11.7 JW Therapeutics

11.7.1 JW Therapeutics Company Detail

11.7.2 JW Therapeutics Business Overview

11.7.3 JW Therapeutics CAR-T Cell Immunotherapies for Cancer Introduction

11.7.4 JW Therapeutics Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.7.5 JW Therapeutics Recent Development

11.8 Protheragen

11.8.1 Protheragen Company Detail

11.8.2 Protheragen Business Overview

11.8.3 Protheragen CAR-T Cell Immunotherapies for Cancer Introduction

11.8.4 Protheragen Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.8.5 Protheragen Recent Development

11.9 EXUMA Biotechnology

11.9.1 EXUMA Biotechnology Company Detail

11.9.2 EXUMA Biotechnology Business Overview

11.9.3 EXUMA Biotechnology CAR-T Cell Immunotherapies for Cancer Introduction

11.9.4 EXUMA Biotechnology Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

11.9.5 EXUMA Biotechnology Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of CD19

Table 3. Key Players of BCMA

Table 4. Key Players of EPCAM

Table 5. Global CAR-T Cell Immunotherapies for Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global CAR-T Cell Immunotherapies for Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global CAR-T Cell Immunotherapies for Cancer Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global CAR-T Cell Immunotherapies for Cancer Market Share by Region (2019-2024)

Table 9. Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global CAR-T Cell Immunotherapies for Cancer Market Share by Region (2025-2030)

Table 11. CAR-T Cell Immunotherapies for Cancer Market Trends

Table 12. CAR-T Cell Immunotherapies for Cancer Market Drivers

Table 13. CAR-T Cell Immunotherapies for Cancer Market Challenges

Table 14. CAR-T Cell Immunotherapies for Cancer Market Restraints

Table 15. Global CAR-T Cell Immunotherapies for Cancer Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global CAR-T Cell Immunotherapies for Cancer Market Share by Players (2019-2024)

Table 17. Global Top CAR-T Cell Immunotherapies for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Cell Immunotherapies for Cancer as of 2023)

Table 18. Ranking of Global Top CAR-T Cell Immunotherapies for Cancer Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by CAR-T Cell Immunotherapies for Cancer Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players CAR-T Cell Immunotherapies for Cancer Product Solution and Service

Table 22. Date of Enter into CAR-T Cell Immunotherapies for Cancer Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global CAR-T Cell Immunotherapies for Cancer Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Type (2019-2024)

Table 26. Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Type (2025-2030)

Table 28. Global CAR-T Cell Immunotherapies for Cancer Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Application (2019-2024)

Table 30. Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global CAR-T Cell Immunotherapies for Cancer Revenue Market Share by Application (2025-2030)

Table 32. North America CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 47. NOVARTIS Company Detail

Table 48. NOVARTIS Business Overview

Table 49. NOVARTIS CAR-T Cell Immunotherapies for Cancer Product

Table 50. NOVARTIS Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 51. NOVARTIS Recent Development

Table 52. Penn Company Detail

Table 53. Penn Business Overview

Table 54. Penn CAR-T Cell Immunotherapies for Cancer Product

Table 55. Penn Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 56. Penn Recent Development

Table 57. Fosun Pharma Company Detail

Table 58. Fosun Pharma Business Overview

Table 59. Fosun Pharma CAR-T Cell Immunotherapies for Cancer Product

Table 60. Fosun Pharma Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 61. Fosun Pharma Recent Development

Table 62. Celgene Corporation Company Detail

Table 63. Celgene Corporation Business Overview

Table 64. Celgene Corporation CAR-T Cell Immunotherapies for Cancer Product

Table 65. Celgene Corporation Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 66. Celgene Corporation Recent Development

Table 67. Legend Biotech Company Detail

Table 68. Legend Biotech Business Overview

Table 69. Legend Biotech CAR-T Cell Immunotherapies for Cancer Product

Table 70. Legend Biotech Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 71. Legend Biotech Recent Development

Table 72. SHEBA Company Detail

Table 73. SHEBA Business Overview

Table 74. SHEBA CAR-T Cell Immunotherapies for Cancer Product

Table 75. SHEBA Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 76. SHEBA Recent Development

Table 77. JW Therapeutics Company Detail

Table 78. JW Therapeutics Business Overview

Table 79. JW Therapeutics CAR-T Cell Immunotherapies for Cancer Product

Table 80. JW Therapeutics Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 81. JW Therapeutics Recent Development

Table 82. Protheragen Company Detail

Table 83. Protheragen Business Overview

Table 84. Protheragen CAR-T Cell Immunotherapies for Cancer Product

Table 85. Protheragen Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 86. Protheragen Recent Development

Table 87. EXUMA Biotechnology Company Detail

Table 88. EXUMA Biotechnology Business Overview

Table 89. EXUMA Biotechnology CAR-T Cell Immunotherapies for Cancer Product

Table 90. EXUMA Biotechnology Revenue in CAR-T Cell Immunotherapies for Cancer Business (2019-2024) & (US$ Million)

Table 91. EXUMA Biotechnology Recent Development

Table 92. Research Programs/Design for This Report

Table 93. Key Data Information from Secondary Sources

Table 94. Key Data Information from Primary Sources

List of Figures

Figure 1. Global CAR-T Cell Immunotherapies for Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global CAR-T Cell Immunotherapies for Cancer Market Share by Type: 2023 VS 2030

Figure 3. CD19 Features

Figure 4. BCMA Features

Figure 5. EPCAM Features

Figure 6. Global CAR-T Cell Immunotherapies for Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global CAR-T Cell Immunotherapies for Cancer Market Share by Application: 2023 VS 2030

Figure 8. Hematological Cancer Case Studies

Figure 9. Solid Tumor Case Studies

Figure 10. Other Oncological Disorders Case Studies

Figure 11. CAR-T Cell Immunotherapies for Cancer Report Years Considered

Figure 12. Global CAR-T Cell Immunotherapies for Cancer Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global CAR-T Cell Immunotherapies for Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global CAR-T Cell Immunotherapies for Cancer Market Share by Region: 2023 VS 2030

Figure 15. Global CAR-T Cell Immunotherapies for Cancer Market Share by Players in 2023

Figure 16. Global Top CAR-T Cell Immunotherapies for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Cell Immunotherapies for Cancer as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by CAR-T Cell Immunotherapies for Cancer Revenue in 2023

Figure 18. North America CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)

Figure 20. United States CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)

Figure 24. Germany CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Share by Region (2019-2030)

Figure 32. China CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)

Figure 40. Mexico CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Share by Country (2019-2030)

Figure 44. Turkey CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia CAR-T Cell Immunotherapies for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. NOVARTIS Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 47. Penn Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 48. Fosun Pharma Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 49. Celgene Corporation Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 50. Legend Biotech Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 51. SHEBA Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 52. JW Therapeutics Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 53. Protheragen Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 54. EXUMA Biotechnology Revenue Growth Rate in CAR-T Cell Immunotherapies for Cancer Business (2019-2024)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

Our Clients